Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Acorda Therapeutics (ACOR)

Acorda Therapeutics (ACOR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 40,706
  • Shares Outstanding, K 9,489
  • Annual Sales, $ 152,970 K
  • Annual Income, $ -99,590 K
  • 60-Month Beta 0.66
  • Price/Sales 0.29
  • Price/Cash Flow N/A
  • Price/Book 0.18
Trade ACOR with:

Options Overview

Details
  • Implied Volatility 148.17%
  • Historical Volatility 102.82%
  • IV Percentile 36%
  • IV Rank 12.37%
  • IV High 517.60% on 09/21/20
  • IV Low 96.01% on 04/20/21
  • Put/Call Vol Ratio 0.44
  • Today's Volume 950
  • Volume Avg (30-Day) 1,058
  • Put/Call OI Ratio 0.49
  • Today's Open Interest 5,575
  • Open Int (30-Day) 5,608

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -2.09
  • Number of Estimates 1
  • High Estimate -2.09
  • Low Estimate -2.09
  • Prior Year -2.22
  • Growth Rate Est. (year over year) +5.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.57 +10.92%
on 07/19/21
6.36 -37.74%
on 07/23/21
-1.23 (-23.70%)
since 06/25/21
3-Month
3.52 +12.50%
on 06/03/21
6.36 -37.74%
on 07/23/21
-0.81 (-16.98%)
since 04/27/21
52-Week
2.53 +56.25%
on 09/14/20
9.84 -59.76%
on 10/20/20
-0.51 (-11.41%)
since 07/27/20

Most Recent Stories

More News
Acorda Therapeutics Announces Agreement to Commercialize INBRIJA(R) in Spain

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into distribution and supply agreements with Esteve Pharmaceuticals S.A (ESTEVE) to commercialize INBRIJA(R) 33 mg (levodopa...

ACOR : 3.96 (-7.69%)
Pain Relief Therapeutics Market 2021 Opportunity Assessment, Business Opportunities, Top Industry Players, Trend and Growth to 2027

ABT : 119.81 (+0.24%)
ACRX : 1.1900 (-1.65%)
ACOR : 3.96 (-7.69%)
AXSM : 52.66 (+1.68%)
BAYRY : 14.9200 (-1.33%)
BDRFF : 119.7000 (unch)
BDSI : 3.64 (+0.55%)
BMY : 67.49 (-0.30%)
COLL : 24.76 (+0.61%)
DEPO : 7.30 (+1.67%)
DRRX : 1.3600 (-1.45%)
EGLT : 0.0315 (-63.37%)
LLY : 243.58 (+0.15%)
FLXN : 6.14 (-1.13%)
GLPG : 60.37 (+0.48%)
HRTX : 12.24 (-2.47%)
KMPH : 10.76 (+0.09%)
MRK : 77.85 (+0.79%)
MESO : 7.04 (-1.68%)
NKTR : 15.91 (-2.03%)
NVS : 91.32 (+0.40%)
ORXOY : 4.4499 (-1.55%)
PFE : 42.10 (+0.69%)
REGN : 581.01 (+0.56%)
VRX.TO : 30.80 (-3.33%)
Insights on the Spinal Cord Trauma Treatment Global Market to 2027 - Featuring Acorda Therapeutics, BioTime and Pfizer Among Others

The "Spinal Cord Trauma Treatment - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

ACOR : 3.96 (-7.69%)
BTX : 10.59 (-0.28%)
Thinking about buying stock in Clearside Biomedical, Acorda Therapeutics, Orphazyme, Nano-X Imaging, or Satsuma Pharmaceuticals?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLSD, ACOR, ORPH, NNOX, and STSA.

ACOR : 3.96 (-7.69%)
CLSD : 5.07 (+1.40%)
NNOX : 27.74 (+0.33%)
ORPH : 4.70 (-7.84%)
STSA : 5.33 (unch)
Acorda Therapeutics Announces Repayment of Convertible Senior Notes

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that on June 15, 2021, it repaid in full its 1.75% Convertible Senior Notes due 2021. Prior to their maturity and repayment, there were $69.0 million...

ACOR : 3.96 (-7.69%)
US Pain Relief Therapeutics Market Share 2021 : Growth Opportunities with Covid-19 Impact Analysis, Business Structure with Top Key Players Size, Development Plans and Challenges Forecast to 2027

The rising prevalence of chronic diseases such as a variety of cancers, osteoarthritis, stomach ulcer, chronic arthritis and diabetes are major key factor which drives the Global Pain Relief Therapeutics...

ABT : 119.81 (+0.24%)
ACRX : 1.1900 (-1.65%)
ACOR : 3.96 (-7.69%)
AXSM : 52.66 (+1.68%)
BAYRY : 14.9200 (-1.33%)
BDRFF : 119.7000 (unch)
BDSI : 3.64 (+0.55%)
BMY : 67.49 (-0.30%)
COLL : 24.76 (+0.61%)
DEPO : 7.30 (+1.67%)
DRRX : 1.3600 (-1.45%)
EGLT : 0.0315 (-63.37%)
LLY : 243.58 (+0.15%)
FLXN : 6.14 (-1.13%)
GLPG : 60.37 (+0.48%)
HRTX : 12.24 (-2.47%)
KMPH : 10.76 (+0.09%)
MRK : 77.85 (+0.79%)
MESO : 7.04 (-1.68%)
NKTR : 15.91 (-2.03%)
NVS : 91.32 (+0.40%)
ORXOY : 4.4499 (-1.55%)
PFE : 42.10 (+0.69%)
REGN : 581.01 (+0.56%)
VRX.TO : 30.80 (-3.33%)
Acorda Therapeutics (ACOR) Reports Q1 Loss, Tops Revenue Estimates

Acorda (ACOR) delivered earnings and revenue surprises of 3.15% and 30.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

ACOR : 3.96 (-7.69%)
Acorda: Q1 Earnings Snapshot

ARDSLEY, N.Y. (AP) _ Acorda Therapeutics Inc. (ACOR) on Thursday reported a loss of $33.5 million in its first quarter.

ACOR : 3.96 (-7.69%)
Acorda Therapeutics Reports First Quarter 2021 Financial Results

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today reported its financial results for the first quarter 2021.

ACOR : 3.96 (-7.69%)
Acorda Therapeutics First Quarter 2021 Update: Webcast/Conference Call Scheduled for May 6, 2021

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its first quarter 2021 update and financial results on Thursday, May 6 at 4:30 p.m. ET.

ACOR : 3.96 (-7.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Acorda Therapeutics, Inc. is a biotechnology company developing and commercializing neurology therapies for Parkinson's disease, migraine and multiple sclerosis. Acorda has a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson's disease and multiple sclerosis....

See More

Key Turning Points

3rd Resistance Point 4.52
2nd Resistance Point 4.37
1st Resistance Point 4.16
Last Price 3.96
1st Support Level 3.80
2nd Support Level 3.65
3rd Support Level 3.44

See More

52-Week High 9.84
Fibonacci 61.8% 7.05
Fibonacci 50% 6.19
Fibonacci 38.2% 5.33
Last Price 3.96
52-Week Low 2.53

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar